Multiple clinical trials, including two phase III trials (NCT02667587 and NCT02617589), are ongoing to assess the potential of PD-1/PD-L1 checkpoint inhibitors, such as pembrolizumab and nivolumab, as monotherapy and combination therapy for glioblastoma (43). The gene discussed is CD274; the disease is glioblastoma.